Corbyn pledges to create state-run generics firm to cut drug prices

22 November 2019 - Labour leader Jeremy Corbyn has included in the party’s election manifesto plans to create a state-run ...

Read more →

Expanding the scope of costs and benefits for economic evaluations in health: some words of caution

18 April 2019 - Discussions regarding the appropriate scope of costs and benefits for inclusion in economic evaluation in healthcare have ...

Read more →

Future unrelated medical costs need to be considered in cost effectiveness analysis

5 March 2019 - New medical technologies that prolong life result in additional health care use in life years gained. Some ...

Read more →

Biosimilar drugs promise to slash health care costs in rich countries

8 November 2018 - The world's top-selling drug now faces biosimilars that are 80% cheaper. ...

Read more →

Cost, context, and decisions in health economics and health technology assessment

18 October 2018 - This study is an attempt to demystify and clarify the idea of cost in health economics ...

Read more →

Biosimilars for insulin: a cost-saving alternative?

11 August 2018 - The expiry of patents on an insulin analogue has opened the market to the production of biosimilar ...

Read more →

Affordability of new technologies: the next frontier

22 March 2018 - Affordability, or rather a lack of it, has become a new buzzword in health policy. It is ...

Read more →

NHS prescription charges are rising – here’s how to keep them down

3 March 2016 - Here’s what you need to know about the increase – and how to get cheaper everyday medicines. ...

Read more →

NHS could claw back £502m if Lyrica ruling upheld, study finds

26 February 2018 - The NHS could reclaim up to £502 million in excess prescribing costs relating to Pfizer’s pregabalin ...

Read more →

CDF to save NHS £140m over five years

31 January 2018 - At least £140 million is expected to be released into the NHS over the next five ...

Read more →

'Drugs are too expensive for the NHS – and people are paying with their lives’

20 December 2017 - Don’t blame the NHS for denying vital medication, say members of a new activist group, Just Treatment. ...

Read more →

One in three RA patients rejecting meds because of cost

6 July 2017 - One in three people with rheumatoid arthritis in England are not taking their medicine as prescribed ...

Read more →

UK audit shows infliximab biosimilars are safe, effective, and cheap

22 September 2016 - Infliximab “biosimilars”—biological therapies engineered to work in the same way as the monoclonal antibody drug infliximab (Remicade)—are ...

Read more →

Unrelated future costs and unrelated future benefits: reflections on NICE Guide to the Methods of Technology Appraisal

3 July 2016 - This editorial considers the vexing issue of ‘unrelated future costs’ (for example, the costs of caring ...

Read more →